ArticleJournal of orthopaedic surgery and research2025
Effects of TGF-β3 on meniscus repair using human amniotic epithelial cells.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMeniscus injury is one of the most common knee diseases, which is managed through conservative and surgical treatments. In recent years, biotherapy has shown great potential to treat various symptoms caused by meniscus injury repair. Human amniotic epithelial cells (hAECs), which are easy to acquire, non-tumorigenic, and high tri-lineage differentiation potential, are a promising cell source for biotherapy and tissue engineering applications. Studies have demonstrated that the Transforming Growth Factor-β3 (TGF-β3) can facilitate chondrocyte differentiation and maturation.
methodsBoth in vitro test and in vivo test were employed. In the in vitro test, human amniotic epithelial cells (hAECs), human amniotic mesenchymal stem cells (hAMCs), and fibrochondrocytes (FCs) were extracted and identified by flow cytometry and immunohistochemistry (IHC). These cells were treated with TGF-β3 for one week, followed by IHC staining and qPCR to explore TGF-β3-induced fibrocartilage formation in hAECs. In the in vivo tests, a meniscus injury model was established based on rabbits, and the Sham, the control (normal saline), and the hAECs + TGF-β3 groups were used. Additionally, the meniscus was collected and checked through general examination and IHC analysis 90 d after surgery.
resultsRoutine transcriptome analysis confirmed that TGF-β3 induced the differentiation of amniotic epithelial cells (hAECs) into fibrochondrocytes through the Wnt signaling pathway. This finding was corroborated using Western blot (WB) and quantitative PCR (QPCR). Among the five experimental groups, the highest expression of target proteins and genes was detected in hAECs + TGF-β3 group, followed by the hAECs + hAMCs + TGF-β3 group, the hAMCs + TGF-β3 group, the hAECs + FCs group, and the FCs group. The observed differences were statistically significant (P < 0.05). In vivo, treatment with hAECs + TGF-β3 facilitated effective repair of damaged menisci.
conclusionshAECs + TGF-β3 can potentially promote the healing of meniscus injuries, laying the foundation for further research to promote its clinical translation.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.